Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Arm, Open-Label Study to Assess the Safety, Efficacy, and Pharmacodynamic Effects of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy

Next Previous
X
Search
Trial Profile

A Single Arm, Open-Label Study to Assess the Safety, Efficacy, and Pharmacodynamic Effects of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jan 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cemdisiran (Primary) ; Pozelimab (Primary) ; Pozelimab (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions
  • Sponsors Regeneron Pharmaceuticals

    • Most Recent Events

    • 12 Dec 2023 Results of psychometric evaluation in patients with Paroxysmal nocturnal hemoglobinuria treated with pozelimab monotherapy or in combination with cemdisiran, presented at the 65th American Society of Hematology Annual Meeting and Exposition.
    • 12 Dec 2023 Results from 52-Week Open-Label Extension presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 03 Nov 2023 According to a Regeneron Pharmaceuticals media release, the updated data from this study will be presented at American Society of Hematology (ASH) Annual Meeting from December 9 to 12 in San Diego, CA.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top